A Bibliometric and Scientific Knowledge Map Study of Migraine Treatment from 2013 to 2022

References

• Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi:10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Burch RC, Buse DC, Lipton RB. Migraine: epidemiology, Burden, and Comorbidity. Neurol Clin. 2019;37(4):631–649. doi:10.1016/j.ncl.2019.06.001
   PubMed Web of Science ®Google Scholar
• Feigin VL, Nichols E, Alam T. Global, regional, and national burden of neurological disorders, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(5):459–480. doi:10.1016/S1474-4422(18)30499-X
   PubMed Web of Science ®Google Scholar
• Vos T, Abajobir AA, Abate KH. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. doi:10.1016/S0140-6736(17)32154-2
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. doi:10.1186/s10194-018-0899-2
   PubMed Web of Science ®Google Scholar
• Ashina M. Migraine. N Engl J Med. 2020;383(19):1866–1876. doi:10.1056/NEJMra1915327
   PubMed Web of Science ®Google Scholar
• González-Hernández A, Marichal-Cancino BA, MaassenVanDenBrink A, Villalón CM. Side effects associated with current and prospective antimigraine pharmacotherapies. Expert Opin Drug Metab Toxicol. 2018;14(1):25–41. doi:10.1080/17425255.2018.1416097
   PubMed Web of Science ®Google Scholar
• Munksgaard SB, Madsen SK, Wienecke T. Treatment of medication overuse headache-A review. Acta Neurol Scand. 2019;139(5):405–414. doi:10.1111/ane.13074
   PubMed Web of Science ®Google Scholar
• Kung D, Rodriguez G, Evans R. Chronic Migraine: diagnosis and Management. Neurol Clin. 2023;41(1):141–159. doi:10.1016/j.ncl.2022.05.005
   PubMed Web of Science ®Google Scholar
• Katsuki M, Yamagishi C, Matsumori Y, et al. Questionnaire-based survey on the prevalence of medication-overuse headache in Japanese one city-Itoigawa study. Neurol Sci. 2022;43(6):3811–3822. doi:10.1007/s10072-021-05831-w
   PubMed Web of Science ®Google Scholar
• Ashina M, Buse DC, Ashina H, et al. Migraine: integrated approaches to clinical management and emerging treatments. Lancet. 2021;397(10283):1505–1518. doi:10.1016/S0140-6736(20)32342-4
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised Phase 2b/3 trial. Lancet Neurol. 2020;19(9):727–737. doi:10.1016/S1474-4422(20)30234-9
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019;381(2):142–149. doi:10.1056/NEJMoa1811090
   PubMed Web of Science ®Google Scholar
• Croop R, Lipton RB, Kudrow D, et al. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021;397(10268):51–60. doi:10.1016/S0140-6736(20)32544-7
   PubMed Web of Science ®Google Scholar
• Ashina M, Doležil D, Bonner JH, et al. A phase 2, randomized, double-blind, placebo-controlled trial of AMG 301, a pituitary adenylate cyclase-activating polypeptide PAC1 receptor monoclonal antibody for migraine prevention. Cephalalgia. 2021;41(1):33–44. doi:10.1177/0333102420970889
   PubMed Web of Science ®Google Scholar
• Xu S, Yu L, Luo X, et al. Manual acupuncture versus sham acupuncture and usual care for prophylaxis of episodic migraine without aura: multicentre, randomised clinical trial. BMJ. 2020;368:m697. doi:10.1136/bmj.m697
   PubMed Web of Science ®Google Scholar
• Stilling JM, Monchi O, Amoozegar F, Debert CT. Transcranial Magnetic and Direct Current Stimulation (TMS/tDCS) for the Treatment of Headache: a Systematic Review. Headache. 2019;59(3):339–357. doi:10.1111/head.13479
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong Z, Wang R, et al. Migraine Prevention Using Different Frequencies of Transcutaneous Occipital Nerve Stimulation: a Randomized Controlled Trial. j Pain. 2017;18(8):1006–1015. doi:10.1016/j.jpain.2017.03.012
   PubMed Web of Science ®Google Scholar
• Yu S, Ran Y, Xiao W, et al. Treatment of migraines with Tianshu capsule: a multi-center, double-blind, randomized, placebo-controlled clinical trial. BMC Complement Altern Med. 2019;19(1):370. doi:10.1186/s12906-019-2775-2
   PubMed Web of Science ®Google Scholar
• Yu S, Ran Y, Wan Q, et al. Efficacy and Safety of Toutongning Capsule in Patients with Migraine: a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. J Alternative Complementary Med. 2019;25(12):1215–1224. doi:10.1089/acm.2018.0500
   PubMed Web of Science ®Google Scholar
• Chen C, Song M. Visualizing a field of research: a methodology of systematic scientometric reviews. PLoS One. 2019;14(10):e0223994. doi:10.1371/journal.pone.0223994
   PubMed Web of Science ®Google Scholar
• van Eck NJ, Waltman L. Software survey: vOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–538. doi:10.1007/s11192-009-0146-3
   PubMed Web of Science ®Google Scholar
• Chen C, Hu Z, Liu S, Tseng H. Emerging trends in regenerative medicine: a scientometric analysis in CiteSpace. Expert Opin Biol Ther. 2012;12(5):593–608. doi:10.1517/14712598.2012.674507
   PubMed Web of Science ®Google Scholar
• Aria M, Cuccurullo C. bibliometrix: an R-tool for comprehensive science mapping analysis. J Informetr. 2017;11(4):959–975. doi:10.1016/j.joi.2017.08.007
   Web of Science ®Google Scholar
• Zhao Y, Huang L, Liu M, Gao H, Li W. Scientific Knowledge Graph of Acupuncture for Migraine: a Bibliometric Analysis from 2000 to 2019. J Pain Res. 2021;14:1985–2000. doi:10.2147/JPR.S314174
   PubMed Web of Science ®Google Scholar
• Bornmann L, Haunschild R. Citation score normalized by cited references (CSNCR): the introduction of a new citation impact indicator. J Informetr. 2016;10(3):875–887. doi:10.1016/j.joi.2016.07.002
   Web of Science ®Google Scholar
• Tepper S, Ashina M, Reuter U, et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 2017;16(6):425–434. doi:10.1016/S1474-4422(17)30083-2
   PubMed Web of Science ®Google Scholar
• Burstein R, Noseda R, Borsook D. Migraine: multiple processes, complex pathophysiology. J Neurosci. 2015;35(17):6619–6629. doi:10.1523/JNEUROSCI.0373-15.2015
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Dodick DW, Bigal ME, et al. Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med. 2017;377(22):2113–2122. doi:10.1056/NEJMoa1709038
   PubMed Web of Science ®Google Scholar
• American Headache Society. The American Headache Society Position Statement On Integrating New Migraine Treatments Into Clinical Practice. Headache. 2019;59:1–18.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Migraine pathophysiology and its clinical implications. Cephalalgia. 2004;24 Suppl 2(2_suppl):2–7. doi:10.1111/j.1468-2982.2004.00892.x
   PubMedGoogle Scholar
• Stovner LJ, Nichols E, Steiner TJ. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954–976. doi:10.1016/S1474-4422(18)30322-3
   PubMed Web of Science ®Google Scholar
• Yu S, Liu R, Zhao G, et al. The prevalence and burden of primary headaches in China: a population-based door-to-door survey. Headache. 2012;52(4):582–591. doi:10.1111/j.1526-4610.2011.02061.x
   PubMed Web of Science ®Google Scholar
• Cernuda-Morollón E, Larrosa D, Ramón C, Vega J, Martínez-Camblor P, Pascual J. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology. 2013;81(14):1191–1196. doi:10.1212/WNL.0b013e3182a6cb72
   PubMed Web of Science ®Google Scholar
• Zhang Q, Han X, Wu H, et al. Dynamic changes in CGRP, PACAP, and PACAP receptors in the trigeminovascular system of a novel repetitive electrical stimulation rat model: relevant to migraine. Mol Pain. 2019;15:1744806918820452. doi:10.1177/1744806918820452
   Web of Science ®Google Scholar
• Ashina M, Hansen JM, Olesen J. Pearls and pitfalls in human pharmacological models of migraine: 30 years’ experience. Cephalalgia. 2013;33(8):540–553. doi:10.1177/0333102412475234
   PubMed Web of Science ®Google Scholar
• Yu S, Kim BK, Wang H, et al. A Phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. J Headache Pain. 2022;23(1):146. doi:10.1186/s10194-022-01514-9
   PubMed Web of Science ®Google Scholar
• Hu B, Li G, Li X, et al. Galcanezumab in episodic migraine: the phase 3, randomized, double-blind, placebo-controlled PERSIST study. J Headache Pain. 2022;23(1):90. doi:10.1186/s10194-022-01458-0
   PubMed Web of Science ®Google Scholar
• Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ. BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia. 2014;34(2):114–125. doi:10.1177/0333102413500727
   PubMed Web of Science ®Google Scholar
• Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137(3):779–794. doi:10.1093/brain/awt369
   PubMedGoogle Scholar
• Han X, Dong Z, Hou L, et al. Interictal plasma pituitary adenylate cyclase-activating polypeptide levels are decreased in migraineurs but remain unchanged in patients with tension-type headache. Clin Chim Acta. 2015;450:151–154. doi:10.1016/j.cca.2015.08.017
   PubMed Web of Science ®Google Scholar
• Hou L, Wan D, Dong Z, et al. Pituitary adenylate cyclase-activating polypeptide expression in peripheral blood mononuclear cells of migraineurs. Cell Biosci. 2016;6(1):40. doi:10.1186/s13578-016-0106-6
   PubMedGoogle Scholar
• Coppola G, Di Renzo A, Tinelli E, et al. Thalamo-cortical network activity during spontaneous migraine attacks. Neurology. 2016;87(20):2154–2160. doi:10.1212/WNL.0000000000003327
   PubMed Web of Science ®Google Scholar
• Coppola G, Di Renzo A, Tinelli E, et al. Thalamo-cortical network activity between migraine attacks: insights from MRI-based microstructural and functional resting-state network correlation analysis. J Headache Pain. 2016;17(1):100. doi:10.1186/s10194-016-0693-y
   PubMedGoogle Scholar
• Andreou AP, Holland PR, Akerman S, Summ O, Fredrick J, Goadsby PJ. Transcranial magnetic stimulation and potential cortical and trigeminothalamic mechanisms in migraine. Brain. 2016;139(7):2002–2014. doi:10.1093/brain/aww118
   PubMedGoogle Scholar
• Kang L, Tang W, Zhang Y, et al. The gut microbiome modulates nitroglycerin-induced migraine-related hyperalgesia in mice. Cephalalgia. 2022;42(6):490–499. doi:10.1177/03331024211050036
   PubMed Web of Science ®Google Scholar
• Miao S, Tang W, Li H, et al. Repeated inflammatory dural stimulation-induced cephalic allodynia causes alteration of gut microbial composition in rats. J Headache Pain. 2022;23(1):71. doi:10.1186/s10194-022-01441-9
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, Smitherman TA. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache 2015;55:21–34. doi:10.1111/head.12482
   PubMed Web of Science ®Google Scholar
• Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS. Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. The Lancet Neurology 2014;13(9):885–892. doi:10.1016/S1474-4422(14)70128-0
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache 2015;55(1):3–20. doi:10.1111/head.12499
   PubMed Web of Science ®Google Scholar
• Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2016;86(19):1818–1826. doi:10.1212/WNL.0000000000002560
   PubMed Web of Science ®Google Scholar
• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a Phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia: an International Journal of Headache 2018;38(6):1026–1037. doi:10.1177/0333102418759786
   PubMed Web of Science ®Google Scholar
• Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR. Evaluation of Galcanezumab for the Prevention of Episodic Migraine: the EVOLVE-1 Randomized Clinical Trial. JAMA Neurology 2018;75(9):1080–1088. doi:10.1001/jamaneurol.2018.1212
   PubMed Web of Science ®Google Scholar
• Zhang Y. The International Classification of Headache Disorders, 3rd edition (beta version). International Journal of Headache 2013;33(1):629–808. doi:10.1177/0333102413485658
   Google Scholar
• Torelli P, Jensen R, Olesen J. Physiotherapy for tension-type headache: a controlled study. Cephalalgia: an International Journal of Headache 2004;24(1):29–36. doi:10.1111/j.1468-2982.2004.00633.x
   PubMed Web of Science ®Google Scholar
• Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007;68(5):343–349. doi:10.1212/01.wnl.0000252808.97649.21
   PubMed Web of Science ®Google Scholar
• Diener HC, Barbanti P, Dahlöf C, Reuter U, Habeck J, Podhorna J. BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a Phase II study. Cephalalgia: an International Journal of Headache 2011;31(5):573–584. doi:10.1177/0333102410388435
   PubMed Web of Science ®Google Scholar